Targeting the Oxytocin System to Treat Addictive Disorders: Rationale and Progress to Date

被引:73
|
作者
Lee, Mary R. [1 ,2 ]
Rohn, Matthew C. H. [1 ,2 ]
Tanda, Gianluigi [3 ]
Leggio, Lorenzo [1 ,2 ,4 ]
机构
[1] NIAAA, Sect Clin Psychoneuroendocrinol & Neuropsychophar, 10 Ctr Dr,MSC 1108, Bethesda, MD 20892 USA
[2] NIDA, 10 Ctr Dr,MSC 1108, Bethesda, MD 20892 USA
[3] NIDA, Medicat Dev Program, Mol Targets & Medicat Discovery Branch, Baltimore, MD 20892 USA
[4] Brown Univ, Ctr Alcohol & Addict Studies, Dept Behav & Social Sci, Providence, RI 02912 USA
基金
美国国家卫生研究院;
关键词
CONDITIONED PLACE PREFERENCE; CHRONIC MORPHINE TREATMENT; COCAINE-SEEKING BEHAVIOR; MEDIAL PREFRONTAL CORTEX; PAIR BOND FORMATION; PROLYL-D-LEUCINE; INTRANASAL OXYTOCIN; NUCLEUS-ACCUMBENS; NEUROHYPOPHYSEAL HORMONES; SUBTHALAMIC NUCLEUS;
D O I
10.1007/s40263-016-0313-z
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The neuropeptide oxytocin plays a role in reward, stress, social affiliation, learning, and memory processes. As such, there is increasing interest in oxytocin as a potential treatment for addictions. The endogenous oxytocin system is itself altered by short- or long-term exposure to drugs of abuse. A large number of preclinical studies in rodents have investigated the effect of oxytocin administration on various drug-induced behaviors to determine whether oxytocin can reverse the neuroadaptations occurring with repeated drug and alcohol use. In addition, the mechanisms by which oxytocin acts to modify the behavioral response to drugs of abuse are beginning to be understood. More recently, a few small clinical studies have been conducted in cocaine, cannabis, and alcohol dependence. This review summarizes the preclinical as well as clinical literature to date on the oxytocin system and its relevance to drug and alcohol addiction.
引用
收藏
页码:109 / 123
页数:15
相关论文
共 50 条
  • [1] Targeting the Oxytocin System to Treat Addictive Disorders: Rationale and Progress to Date
    Mary R. Lee
    Matthew C. H. Rohn
    Gianluigi Tanda
    Lorenzo Leggio
    [J]. CNS Drugs, 2016, 30 : 109 - 123
  • [2] Targeting the Glutamatergic System to Treat Major Depressive Disorder Rationale and Progress to Date
    Mathews, Daniel C.
    Henter, Ioline D.
    Zarate, Carlos A., Jr.
    [J]. DRUGS, 2012, 72 (10) : 1313 - 1333
  • [3] Targeting Retinoid Receptors to Treat Schizophrenia: Rationale and Progress to Date
    Lerner, Vladimir
    McCaffery, Peter J. A.
    Ritsner, Michael S.
    [J]. CNS DRUGS, 2016, 30 (04) : 269 - 280
  • [4] Targeting Retinoid Receptors to Treat Schizophrenia: Rationale and Progress to Date
    Vladimir Lerner
    Peter J. A. McCaffery
    Michael S. Ritsner
    [J]. CNS Drugs, 2016, 30 : 269 - 280
  • [5] Targeting the Nicotinic Cholinergic System to Treat Attention-Deficit/Hyperactivity Disorder: Rationale and Progress to Date
    Alexandra S. Potter
    Geoffrey Schaubhut
    Megan Shipman
    [J]. CNS Drugs, 2014, 28 : 1103 - 1113
  • [6] Targeting the Nicotinic Cholinergic System to Treat Attention-Deficit/Hyperactivity Disorder: Rationale and Progress to Date
    Potter, Alexandra S.
    Schaubhut, Geoffrey
    Shipman, Megan
    [J]. CNS DRUGS, 2014, 28 (12) : 1103 - 1113
  • [7] Targeting the Glutamatergic System to Treat Major Depressive DisorderRationale and Progress to Date
    Daniel C. Mathews
    Ioline D. Henter
    Carlos A. Zarate
    [J]. Drugs, 2012, 72 : 1313 - 1333
  • [8] Targeting IL-23 for IBD: Rationale and Progress to Date
    Sudheer K. Vuyyuru
    Lisa M. Shackelton
    Jurij Hanzel
    Christopher Ma
    Vipul Jairath
    Brian G. Feagan
    [J]. Drugs, 2023, 83 : 873 - 891
  • [9] Targeting IL-23 for IBD: Rationale and Progress to Date
    Vuyyuru, Sudheer K.
    Shackelton, Lisa M.
    Hanzel, Jurij
    Ma, Christopher
    Jairath, Vipul
    Feagan, Brian G.
    [J]. DRUGS, 2023, 83 (10) : 873 - 891
  • [10] Targeting the Serotonin 5-HT7 Receptor in the Search for Treatments for CNS Disorders: Rationale and Progress to Date
    Nikiforuk, Agnieszka
    [J]. CNS DRUGS, 2015, 29 (04) : 265 - 275